Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Velcade bortezomib: Phase III data

The Phase III HOVON-65/GMMG-HD4 trial in 626 patients with newly diagnosed symptomatic MM showed that the Velcade-based treatment regimen led to superior PFS at 36

Read the full 257 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE